Printed from https://ideas.repec.org/s/spr/drugsa6.html
Content
January 2017, Volume 40, Issue 1
- 65-80 Role of Preemptive Genotyping in Preventing Serious Adverse Drug Events in South Korean Patients
by Grace Juyun Kim & Soo Youn Lee & Ji Hye Park & Brian Y. Ryu & Ju Han Kim - 81-90 Current Safety Concerns with Human Papillomavirus Vaccine: A Cluster Analysis of Reports in VigiBase®
by Rebecca E. Chandler & Kristina Juhlin & Jonas Fransson & Ola Caster & I. Ralph Edwards & G. Niklas Norén - 91-100 The Role of Hemoglobin Laboratory Test Results for the Detection of Upper Gastrointestinal Bleeding Outcomes Resulting from the Use of Medications in Observational Studies
by Elisabetta Patorno & Joshua J. Gagne & Christine Y. Lu & Kevin Haynes & Andrew T. Sterrett & Jason Roy & Xingmei Wang & Marsha A. Raebel
December 2016, Volume 39, Issue 12
- 1161-1162 On Designs for Vaccine Surveillance
by Robert W. Platt - 1163-1174 Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs
by Emanuele D’Amico & Aurora Zanghì & Carmela Leone & Hayrettin Tumani & Francesco Patti - 1175-1187 Risk–Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies
by Emanuel Raschi & Matteo Bianchin & Walter Ageno & Roberto De Ponti & Fabrizio De Ponti - 1189-1195 Completeness of Spontaneous Adverse Drug Reaction Reports Sent by General Practitioners to a Regional Pharmacovigilance Centre: A Descriptive Study
by Geneviève Durrieu & Julien Jacquot & Mathilde Mège & Emmanuelle Bondon-Guitton & Vanessa Rousseau & François Montastruc & Jean-Louis Montastruc - 1197-1209 Vaccine Case–Population: A New Method for Vaccine Safety Surveillance
by Hélène Théophile & Nicholas Moore & Philip Robinson & Bernard Bégaud & Antoine Pariente - 1211-1227 Estimating Herbal Product Authentication and Adulteration in India Using a Vouchered, DNA-Based Biological Reference Material Library
by Dhivya Shanmughanandhan & Subramanyam Ragupathy & Steven G. Newmaster & Saravanan Mohanasundaram & Ramalingam Sathishkumar - 1229-1237 The Risk of Achilles or Biceps Tendon Rupture in New Statin Users: A Propensity Score-Matched Sequential Cohort Study
by Julia Spoendlin & J. Bradley Layton & Mallika Mundkur & Christian Meier & Susan S. Jick & Christoph R. Meier - 1239-1250 Knowledge of Adverse Drug Reaction Reporting Among Healthcare Professionals in Bhutan: A Cross-Sectional Survey
by Choki Dorji & Pramote Tragulpiankit & Arthorn Riewpaiboon & Tashi Tobgay
November 2016, Volume 39, Issue 11
- 1043-1051 National ADR Monitoring System in China
by Yongfang Hou & Xinling Li & Guizhi Wu & Xiaofei Ye - 1053-1072 Drug–Drug Interactions, Effectiveness, and Safety of Hormonal Contraceptives in Women Living with HIV
by Kimberly K. Scarsi & Kristin M. Darin & Catherine A. Chappell & Stephanie M. Nitz & Mohammed Lamorde - 1073-1091 Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas
by Rashmi R. Shah - 1093-1104 Pattern of Onset and Risk Factors for Peripheral Oedema During Vildagliptin Use: Analysis from the Vildagliptin Prescription–Event Monitoring Study in England
by Deborah Layton & Abigail L. Coughtrie & Naseer Qayum & Saad A. W. Shakir - 1105-1116 Patient Reporting of Adverse Drug Reactions: An International Survey of National Competent Authorities’ Views and Needs
by Cristiano Matos & Linda Härmark & Florence Hunsel - 1117-1127 A Survey of Adverse Event Reporting Practices Among US Healthcare Professionals
by Stella Stergiopoulos & Carrie A. Brown & Thomas Felix & Gustavo Grampp & Kenneth A. Getz - 1129-1137 Prevention of Medication Errors in Hospitalized Patients: The Japan Adverse Drug Events Study
by Chihiro Noguchi & Mio Sakuma & Yoshinori Ohta & David W. Bates & Takeshi Morimoto - 1139-1149 Association Between the Occurrence of Adverse Drug Events and Modification of First-Line Highly Active Antiretroviral Therapy in Ghanaian HIV Patients
by Raymond A. Tetteh & Edmund T. Nartey & Margaret Lartey & Aukje K. Mantel-Teeuwisse & Hubert G. M. Leufkens & Barbara A. Yankey & Alexander N. O. Dodoo - 1151-1152 Comment on: “Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence”
by Alain Braillon - 1153-1154 Authors’ Reply to Alain Braillon’s Comment on “Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence”
by Julia M. A. Sinclair & Sophia E. Chambers & David S. Baldwin
October 2016, Volume 39, Issue 10
- 883-890 Patient-Reported Safety Information: A Renaissance of Pharmacovigilance?
by Linda Härmark & June Raine & Hubert Leufkens & I. Ralph Edwards & Ugo Moretti & Viola Macolic Sarinic & Agnes Kant - 891-894 Pacific Island Pharmacovigilance: The Need for a Different Approach
by John McEwen & Lasse S. Vestergaard & Amanda L. C. Sanburg - 895-901 Causality Assessment in Premarketing Drug Clinical Trials: Regulatory Evolution in the USA and Ongoing Concerns
by Stephen A. Goldman - 903-924 Neonatal Adaptation Issues After Maternal Exposure to Prescription Drugs: Withdrawal Syndromes and Residual Pharmacological Effects
by Irma Convertino & Alice Capogrosso Sansone & Alessandra Marino & Maria T. Galiulo & Stefania Mantarro & Luca Antonioli & Matteo Fornai & Corrado Blandizzi & Marco Tuccori - 925-943 Hepatic Safety of Atypical Antipsychotics: Current Evidence and Future Directions
by Mahmoud Slim & Inmaculada Medina-Caliz & Andres Gonzalez-Jimenez & M. Rosario Cabello & Fermin Mayoral-Cleries & M. Isabel Lucena & Raul J. Andrade - 945-957 Neuropsychiatric Effects of HIV Antiviral Medications
by Glenn J. Treisman & Olivia Soudry - 959-976 Targeted Spontaneous Reporting: Assessing Opportunities to Conduct Routine Pharmacovigilance for Antiretroviral Treatment on an International Scale
by Beth Rachlis & Rakhi Karwa & Celia Chema & Sonak Pastakia & Sten Olsson & Kara Wools-Kaloustian & Beatrice Jakait & Mercy Maina & Marcel Yotebieng & Nagalingeswaran Kumarasamy & Aimee Freeman & Nathalie de Rekeneire & Stephany N. Duda & Mary-Ann Davies & Paula Braitstein - 977-988 Innovative Digital Tools and Surveillance Systems for the Timely Detection of Adverse Events at the Point of Care: A Proof-of-Concept Study
by Christian Hoppe & Patrick Obermeier & Susann Muehlhans & Maren Alchikh & Lea Seeber & Franziska Tief & Katharina Karsch & Xi Chen & Sindy Boettcher & Sabine Diedrich & Tim Conrad & Bron Kisler & Barbara Rath
September 2016, Volume 39, Issue 9
- 779-785 The Patient’s Voice in Pharmacovigilance: Pragmatic Approaches to Building a Patient-Centric Drug Safety Organization
by Meredith Y. Smith & Isma Benattia - 787-799 Benefit–Risk Assessment of Fish Oil in Preventing Cardiovascular Disease
by Bill Lands - 801-821 Drug-Induced Liver Injury: Highlights from a Review of the 2015 Literature
by Philip Sarges & Joshua M Steinberg & James H Lewis - 823-840 Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster
by Kunihiro Yamaoka - 841-845 Drug Interactions of Direct-Acting Oral Anticoagulants
by John Leonard Fitzgerald & Laurence Guy Howes - 847-857 Adverse-Drug-Reaction-Related Hospitalisations in Developed and Developing Countries: A Review of Prevalence and Contributing Factors
by Mulugeta Tarekegn Angamo & Leanne Chalmers & Colin M. Curtain & Luke R. E. Bereznicki - 859-872 Active Surveillance versus Spontaneous Reporting for First-Line Antiretroviral Medicines in Namibia: A Cost–Utility Analysis
by Marita Mann & Assegid Mengistu & Johannes Gaeseb & Evans Sagwa & Greatjoy Mazibuko & Joseph B. Babigumira & Louis P. Garrison & Andy Stergachis - 873-881 Drug Safety Monitoring in Children: Performance of Signal Detection Algorithms and Impact of Age Stratification
by Osemeke U. Osokogu & Caitlin Dodd & Alexandra Pacurariu & Florentia Kaguelidou & Daniel Weibel & Miriam C. J. M. Sturkenboom
August 2016, Volume 39, Issue 8
- 715-727 Contemporary Reflections on the Safety of Long-Term Aspirin Treatment for the Secondary Prevention of Cardiovascular Disease
by Alexander C. Fanaroff & Matthew T. Roe - 729-744 Diagnosis and Management of Drug-Induced Liver Injury (DILI) in Patients with Pre-Existing Liver Disease
by Rolf Teschke & Gaby Danan - 745-748 Age at First Rotavirus Vaccination and Risk of Intussusception in Infants: A Public Health Modeling Analysis
by Chee Fu Yung & Chia Yin Chong & Koh Cheng Thoon - 749-754 Risk of Liver Injury Associated with Green Tea Extract in SLIMQUICK® Weight Loss Products: Results from the DILIN Prospective Study
by Elizabeth X. Zheng & Simona Rossi & Robert J. Fontana & Raj Vuppalanchi & Jay H. Hoofnagle & Ikhlas Khan & Victor J. Navarro - 755-762 Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis
by Megan E. B. Clowse & Steven R. Feldman & John D. Isaacs & Alexandra B. Kimball & Vibeke Strand & Richard B. Warren & Daniel Xibillé & Yan Chen & Donald Frazier & Jamie Geier & James Proulx & Amy Marren - 763-768 Artesunate/Amodiaquine-Induced Acute Extrapyramidal Reactions in Children and Younger Adults: Case Series Assessment
by Mulugeta Russom & Dawit Tesfai & Semere Gebregiorgis & Abdulmumini Usman & Selam Mihreteab & Iyassu Bahta & Elsa Mekonnen & Selamawit Ghebrehiwet & Gelila Abrham - 769-776 The Impact of Experiencing Adverse Drug Reactions on the Patient’s Quality of Life: A Retrospective Cross-Sectional Study in the Netherlands
by Leàn Rolfes & Florence Hunsel & Katja Taxis & Eugène Puijenbroek - 777-778 Is Earlier Signal Detection Always Better?
by Alan M. Hochberg & Stella Stergiopoulos
July 2016, Volume 39, Issue 7
- 589-611 Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal Impairment
by Elise J. Smolders & Clara T. M. M. Kanter & Bart Hoek & Joop E. Arends & Joost P. H. Drenth & David M. Burger - 613-626 Neurocognitive Adverse Effects of Anesthesia in Adults and Children: Gaps in Knowledge
by Christopher G. Ward & Roderic G. Eckenhoff - 627-645 Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence
by Julia M. A. Sinclair & Sophia E. Chambers & Celia J. Shiles & David S. Baldwin
June 2016, Volume 39, Issue 6
- 491-500 Medication Errors: New EU Good Practice Guide on Risk Minimisation and Error Prevention
by Thomas Goedecke & Kathryn Ord & Victoria Newbould & Sabine Brosch & Peter Arlett - 501-508 Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update
by Maria Gabriella Matera & Paola Rogliani & Luigino Calzetta & Mario Cazzola - 509-516 The Safety of Prochlorperazine in Children: A Systematic Review and Meta-Analysis
by Melissa Lau Moon Lin & Paula D. Robinson & Jacqueline Flank & Lillian Sung & L. Lee Dupuis
May 2016, Volume 39, Issue 5
- 371-373 Measuring Signal Detection Performance: Can We Trust Negative Controls and Do We Need Them?
by Jim Slattery - 375-380 Maximizing the Post-Approval Safety of Flibanserin: A Role for Regulators, Clinicians, and Patients
by Sheriza N. Baksh & Walid F. Gellad & G. Caleb Alexander - 381-399 Side Effects and Efficacy of Neuraxial Opioids in Pregnant Patients at Delivery: A Comprehensive Review
by Sarah Armstrong & Roshan Fernando - 401-407 Dipeptidyl Peptidase (DPP)-4 Inhibitor-Induced Arthritis/Arthralgia: A Review of Clinical Cases
by Annamaria Mascolo & Concetta Rafaniello & Liberata Sportiello & Maurizio Sessa & Daniela Cimmaruta & Francesco Rossi & Annalisa Capuano - 409-419 Safety Profile of Atorvastatin 80 mg: A Meta-Analysis of 17 Randomized Controlled Trials in 21,910 Participants
by Haixia Li & Cailian Wang & Shuo Zhang & Sihao Sun & Ruifei Li & Meijuan Zou & Gang Cheng - 421-432 Evidence of Misclassification of Drug–Event Associations Classified as Gold Standard ‘Negative Controls’ by the Observational Medical Outcomes Partnership (OMOP)
by Manfred Hauben & Jeffrey K. Aronson & Robin E. Ferner - 433-441 An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval
by Tal Lorberbaum & Kevin J. Sampson & Raymond L. Woosley & Robert S. Kass & Nicholas P. Tatonetti - 443-454 Social Media Listening for Routine Post-Marketing Safety Surveillance
by Gregory E. Powell & Harry A. Seifert & Tjark Reblin & Phil J. Burstein & James Blowers & J. Alan Menius & Jeffery L. Painter & Michele Thomas & Carrie E. Pierce & Harold W. Rodriguez & John S. Brownstein & Clark C. Freifeld & Heidi G. Bell & Nabarun Dasgupta - 455-464 Allergy-Like Immediate Reactions with Herbal Medicines: A Retrospective Study Using Data from VigiBase®
by Jitka Pokladnikova & Ronald H. B. Meyboom & Ricarda Meincke & David Niedrig & Stefan Russmann - 465-466 Comment on: “Drug-Induced Hyperglycaemia and Diabetes”
by Jean-Louis Montastruc & Leila Chebane & Haleh Bagheri - 467-467 Authors’ Reply to Montastruc et al.: “Drug-Induced Hyperglycaemia and Diabetes”
by Neila Fathallah & Raoudha Slim & Sofiene Larif & Houssem Hmouda & Chaker Ben Salem
April 2016, Volume 39, Issue 4
- 277-280 Vulnerable Patients and Potential Harms: The Contribution of Observational Research
by Deborah Layton - 281-285 Pharmacovigilance is … Vigilance
by I. Ralph Edwards & Rachida Soulayamani Bencheikh - 287-294 Comparative Safety and Tolerability of Prostacyclins in Pulmonary Hypertension
by Caroline O’Connell & David Amar & Athénaïs Boucly & Laurent Savale & Xavier Jaïs & Marie-Camille Chaumais & David Montani & Marc Humbert & Gérald Simonneau & Olivier Sitbon - 295-305 Quantitative Risk–Benefit Analysis of Probiotic Use for Irritable Bowel Syndrome and Inflammatory Bowel Disease
by William E. Bennett - 307-321 Risk of Seizures Associated with Antidepressant Use in Patients with Depressive Disorder: Follow-up Study with a Nested Case–Control Analysis Using the Clinical Practice Research Datalink
by Marlene Bloechliger & Alessandro Ceschi & Stephan Rüegg & Hugo Kupferschmidt & Stephan Kraehenbuehl & Susan S. Jick & Christoph R. Meier & Michael Bodmer - 323-333 Safety of Intranasal Quadrivalent Live Attenuated Influenza Vaccine (QLAIV) in Children and Adolescents: A Pilot Prospective Cohort Study in England
by Rhian McNaughton & Elizabeth Lynn & Vicki Osborne & Abigail Coughtrie & Deborah Layton & Saad Shakir - 335-345 Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report Characteristics Between Africa and the Rest of the World: Analyses of Spontaneous Reports in VigiBase®
by Haggar H. Ampadu & Jarno Hoekman & Marieke L. Bruin & Shanthi N. Pal & Sten Olsson & Daniele Sartori & Hubert G. M. Leufkens & Alexander N. O. Dodoo - 347-354 Sequence Symmetry Analysis as a Signal Detection Tool for Potential Heart Failure Adverse Events in an Administrative Claims Database
by Izyan A. Wahab & Nicole L. Pratt & Lisa Kalisch Ellett & Elizabeth E. Roughead - 355-364 Performance of Stratified and Subgrouped Disproportionality Analyses in Spontaneous Databases
by Suzie Seabroke & Gianmario Candore & Kristina Juhlin & Naashika Quarcoo & Antoni Wisniewski & Ramin Arani & Jeffery Painter & Philip Tregunno & G. Niklas Norén & Jim Slattery - 365-365 Comment on ‘The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project’
by Alain Braillon - 367-368 Authors’ Reply to Alain Braillon’s Comment on “The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project”
by Emanuel Raschi & Elisabetta Poluzzi & Francesco Salvo & Ugo Moretti & Fabrizio Ponti - 369-369 Erratum to: Renal and Bone Adverse Effects of a Tenofovir-Based Regimen in the Treatment of HIV-Infected Children: A Systematic Review
by Rose I. Okonkwo & Anita E. Weidmann & Emmanuel E. Effa
March 2016, Volume 39, Issue 3
- 193-197 Risk of Inflammatory Bowel Disease with Oral Contraceptives and Menopausal Hormone Therapy: Current Evidence and Future Directions
by Hamed Khalili - 199-208 Hepatotoxicity Associated with the Use of Anti-TNF-α Agents
by Joshua B. French & Maurizio Bonacini & Marwan Ghabril & David Foureau & Herbert L. Bonkovsky - 209-218 Renal and Bone Adverse Effects of a Tenofovir-Based Regimen in the Treatment of HIV-Infected Children: A Systematic Review
by Rose I. Okonkwo & Anita E. Weidmann & Emmanuel E. Effa - 219-230 Post-Marketing Benefit–Risk Assessment of Rotavirus Vaccination in Japan: A Simulation and Modelling Analysis
by Edouard Ledent & Alfons Lieftucht & Hubert Buyse & Keiji Sugiyama & Michael Mckenna & Katsiaryna Holl - 231-240 Social Media Mining for Toxicovigilance: Automatic Monitoring of Prescription Medication Abuse from Twitter
by Abeed Sarker & Karen O’Connor & Rachel Ginn & Matthew Scotch & Karen Smith & Dan Malone & Graciela Gonzalez - 241-250 Clinicians’ Reports in Electronic Health Records Versus Patients’ Concerns in Social Media: A Pilot Study of Adverse Drug Reactions of Aspirin and Atorvastatin
by Maxim Topaz & Kenneth Lai & Neil Dhopeshwarkar & Diane L. Seger & Roee Sa’adon & Foster Goss & Ronen Rozenblum & Li Zhou - 251-260 A Method for the Minimization of Competition Bias in Signal Detection from Spontaneous Reporting Databases
by Mickael Arnaud & Francesco Salvo & Ismaïl Ahmed & Philip Robinson & Nicholas Moore & Bernard Bégaud & Pascale Tubert-Bitter & Antoine Pariente - 261-270 Use of Prescription Drug Samples in the USA: A Descriptive Study with Considerations for Pharmacoepidemiology
by Christian Hampp & Patty Greene & Simone P. Pinheiro - 271-276 The 9th International Congress on Cutaneous Adverse Drug Reactions at the 23rd World Congress of Dermatology in Vancouver, 2015
by Roni P. Dodiuk-Gad & Cristina Olteanu & Wen-Hung Chung & Neil H. Shear
February 2016, Volume 39, Issue 2
- 93-107 Mortality Risk of Hypnotics: Strengths and Limits of Evidence
by Daniel F. Kripke - 109-116 Appropriate Polypharmacy and Medicine Safety: When Many is not Too Many
by Cathal A. Cadogan & Cristín Ryan & Carmel M. Hughes - 117-130 Testosterone Replacement Therapy and Mortality in Older Men
by G. I. Hackett - 131-146 Tools for Assessing Potential Significance of Pharmacist Interventions: A Systematic Review
by Thi-Ha Vo & Bruno Charpiat & Claire Catoire & Michel Juste & Renaud Roubille & François-Xavier Rose & Sébastien Chanoine & Jean-Luc Bosson & Ornella Conort & Benoît Allenet & Pierrick Bedouch - 147-157 Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies
by Michael W. Dunne & George H. Talbot & Helen W. Boucher & Mark Wilcox & Sailaja Puttagunta - 159-169 Adverse Drug Reactions Reported to a National HIV & Tuberculosis Health Care Worker Hotline in South Africa: Description and Prospective Follow-Up of Reports
by Christine Njuguna & Annemie Stewart & Johannes P. Mouton & Marc Blockman & Gary Maartens & Annoesjka Swart & Briony Chisholm & Jackie Jones & Mukesh Dheda & Ehimario U. Igumbor & Karen Cohen - 171-184 Consumer Understanding, Preferences, and Responses to Different Versions of Drug Safety Messages in the United States: A Randomized Controlled Trial
by Lauren McCormack & R. Craig Lefebvre & Carla Bann & Olivia Taylor & Paula Rausch - 185-192 Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports
by Kevin Klein & Joep H. G. Scholl & Niels S. Vermeer & André W. Broekmans & Eugène P. Puijenbroek & Marie L. Bruin & Pieter Stolk
January 2016, Volume 39, Issue 1
- 1-3 What Is the Plural of a ‘Yellow’ Anecdote?
by Stephen J. W. Evans - 5-13 Reversal Strategies for NOACs: State of Development, Possible Clinical Applications and Future Perspectives
by Steen Husted & Freek W. A. Verheugt & Willemijn J. Comuth - 15-27 Advances in the Pharmacogenomics of Adverse Drug Reactions
by Susannah L. Collins & Daniel F. Carr & Munir Pirmohamed - 29-43 An Empirical Approach to Explore the Relationship Between Measures of Disproportionate Reporting and Relative Risks from Analytical Studies
by Miguel-Angel Maciá-Martínez & Francisco J. Abajo & Gilly Roberts & Jim Slattery & Bharat Thakrar & Antoni F. Z. Wisniewski - 45-57 Feasibility of Prioritizing Drug–Drug-Event Associations Found in Electronic Health Records
by Juan M. Banda & Alison Callahan & Rainer Winnenburg & Howard R. Strasberg & Aurel Cami & Ben Y. Reis & Santiago Vilar & George Hripcsak & Michel Dumontier & Nigam Haresh Shah - 59-68 The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project
by Emanuel Raschi & Elisabetta Poluzzi & Francesco Salvo & Ariola Koci & Marc Suling & Stefania Antoniazzi & Luisella Perina & Lorna Hazell & Ugo Moretti & Miriam Sturkenboom & Edeltraut Garbe & Antoine Pariente & Fabrizio Ponti - 69-78 Psychiatric Disorders and Montelukast in Children: A Disproportionality Analysis of the VigiBase®
by Ana Aldea Perona & Mar García-Sáiz & Emilio Sanz Álvarez - 79-87 The Association Between Potentially Inappropriate Prescribing and Medication-Related Hospital Admissions in Older Patients: A Nested Case Control Study
by C. A. K. Stelt & A. M. A. Vermeulen Windsant-van den Tweel & A. C. G. Egberts & P. M. L. A. Bemt & A. J. Leendertse & W. A. J. J. Hermens & R. J. Marum & H. J. Derijks - 89-90 Comment on: “Indigenous Medicine Use for Sex Selection During Pregnancy and Risk of Congenital Malformations: A Population-Based Case–Control Study in Haryana, India”
by Sibel Yöntem & Belgin Maden-Tastan & Yusuf Cem Kaplan - 91-92 Authors’ Reply to Sibel Yöntem and Colleagues’ Comment on “Indigenous Medicine Use for Sex Selection During Pregnancy and Risk of Congenital Malformations: A Population-Based Case-Control Study in Haryana, India”
by Sutapa Bandyopadhyay Neogi & Preeti H. Negandhi & Ravi Kant Gupta & Abhijit Ganguli & Sanjay Zodpey & Amarjeet Singh & Rakesh Gupta
July 2015, Volume 38, Issue 7
- 611-620 DNA Barcoding and Pharmacovigilance of Herbal Medicines
by Hugo J. Boer & Mihael C. Ichim & Steven G. Newmaster
October 2014, Volume 37, Issue 10
- 743-759 Teaching Pharmacovigilance: the WHO-ISoP Core Elements of a Comprehensive Modular Curriculum
by Jürgen Beckmann & Ulrich Hagemann & Priya Bahri & Andrew Bate & Ian Boyd & Gerald Dal Pan & Brian Edwards & I. Edwards & Kenneth Hartigan-Go & Marie Lindquist & John McEwen & Yola Moride & Sten Olsson & Shanthi Pal & Rachida Soulaymani-Bencheikh & Marco Tuccori & Claudia Vaca & Ian Wong - 761-764 Pharmacovigilance for a Revolving World: Prospects of Patient-Generated Data on the Internet
by G. Norén - 765-770 Pharmacovigilance in China: Current Situation, Successes and Challenges
by Li Zhang & Lisa Wong & Ying He & Ian Wong - 771-776 Restrictive Reimbursement Policies: Bias Implications for Claims-Based Drug Safety Studies
by Joshua Gagne - 777-790 Text Mining for Adverse Drug Events: the Promise, Challenges, and State of the Art
by Rave Harpaz & Alison Callahan & Suzanne Tamang & Yen Low & David Odgers & Sam Finlayson & Kenneth Jung & Paea LePendu & Nigam Shah - 791-804 The Safety of Olanzapine in Young Children: A Systematic Review and Meta-Analysis
by Jacqueline Flank & Lillian Sung & Christopher Dvorak & Wendy Spettigue & L. Dupuis - 805-813 Comparison of Pregnancy and Lactation Labeling for Attention-Deficit Hyperactivity Disorder Drugs Marketed in Australia, the USA, Denmark, and the UK
by Pernille Warrer & Lise Aagaard & Ebba Hansen - 815-829 Safety Profile of Dapagliflozin for Type 2 Diabetes: Pooled Analysis of Clinical Studies for Overall Safety and Rare Events
by Agata Ptaszynska & Kristina Johnsson & Shamik Parikh & Tjerk Bruin & Anne Apanovitch & James List
September 2012, Volume 35, Issue 9
- 695-709 Early Investigation of QTc Liability
by Rashmi R. Shah & Joel Morganroth - 711-724 A Pathway to Improved Prospective Observational Post-Authorization Safety Studies
by Victor A. Kiri - 725-731 A Computerized Physician Order Entry Set Designed to Improve Safety of Intravenous Haloperidol Utilization
by Andrew J. Muzyk & Sarah K. Rivelli & Wei Jiang & Heather Heinz & Amber Rayfield & Jane P. Gagliardi - 733-743 Methods for Retrospective Detection of Drug Safety Signals and Adverse Events in Electronic General Practice Records
by Andrew Tomlin & David Reith & Susan Dovey & Murray Tilyard - 745-758 Drug Interactions in Dying Patients
by Sebastian Frechen & Anna Zoeller & Klaus Ruberg & Raymond Voltz & Jan Gaertner - 759-767 Drug Fever
by Dominique Vodovar & Christine LeBeller & Bruno Mégarbane & Agnes Lillo-Le-Louet & Thomas Hanslik - 769-781 Incidence and Economic Burden of Adverse Drug Reactions among Elderly Patients in Ontario Emergency Departments
by Chen Wu & Chaim M. Bell & Walter P. Wodchis